Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Illinois Pain Institute Believes State is Going Down Wrong Path with Passage of Medical Marijuana Legislation SB336
  • USA - English


News provided by

US Lead Network

Feb 19, 2018, 06:00 ET

Share this article

Share toX

Share this article

Share toX


CHICAGO (PRWEB) February 19, 2018 -- On Wednesday, February 7, 2018, the Illinois Senate Executive Committee passed SB336 in a 16-1 decision. SB336, if signed into law, would allow individuals who are prescribed opioids to apply for medical marijuana under the state’s medical marijuana program, with the belief that marijuana is a safer and more preferred alternative to opioids.

“This is reminiscent of what happened in the ‘90s with opioids,” says Dr. John Prunskis, co-founder of the Illinois Pain Institute and The Regenerative Stem Cell Institute. “This is just another way to mask pain and avoid the responsibility of diagnosing and fixing the patient’s painful condition.”

Post this

In the same week, the Illinois Department of Health sought to appeal a ruling by a Cook County judge that added “intractable” – or chronic and severe – pain to the list of acceptable conditions for medical marijuana under the state’s program. What SB336 and the addition of intractable pain to the list of more than 40 qualifying conditions for receiving medical marijuana tell us is that the state is losing track of what pain treatment is really about –fixing the source of pain, and is going down a dangerous path that we’ve seen fail before.

“This is reminiscent of what happened in the ‘90s with opioids,” says Dr. John Prunskis, co-founder of the Illinois Pain Institute and The Regenerative Stem Cell Institute. “This is just another way to mask pain and avoid the responsibility of diagnosing and fixing the patient’s painful condition.”

While the Illinois Pain Institute does not oppose medical marijuana when appropriate, SB336 opens the door to overuse and abuse of the drug while avoiding the key issue: diagnosing and treating the source of the pain. At the Illinois Pain Institute, physicians use imaging, interventions, and preferentially non-opiate medications to fix and treat the underlying problem, instead of masking symptoms.

“If you have rust on your car and the mechanic tells you to just cover it with paint you might feel better about it in the short term, but it doesn’t fix the problem and it will slowly catch up to you,” Prunskis adds.

Medical marijuana, like opioids, is frequently a quick fix for painful symptoms, and it fails to address root causes of pain or support long-term therapeutic outcomes. And while marijuana has less potential for drug-related overdoses and deaths than opioids, innovations in diagnostics and treatment mean that we have an increasing number of preferred alternatives for patients that offer sustainable relief without relying on mood-altering substances.

The physicians at the Illinois Pain Institute encourage Illinois lawmakers to think more broadly about the treatment of chronic pain and support the platform that diagnosing and fixing the problem is preferential to masking it.

Contact:
Owen
847-289-8822
owen(at)illinoispain.com
IllinoisPain.com

ABOUT ILLINOIS PAIN INSTITUTE

Started in 1992, Illinois Pain Institute is the longest established multi-site Interventional Pain Practice in the Chicago area. The Chicago pain management practice has grown to include seven locations in the Chicago suburbs: Elgin, Lake Barrington, McHenry, Itasca, Libertyville, Huntley and Elmhurst.

IPI has been an eight-time winner of the Castle Connolly “Top Doctor” award, as seen in Chicago Magazine and the New York Times. The practice is completely focused on diagnosing, identifying and fixing the problem and not masking it. IPI physicians provide precise diagnosis and treatment of back pain, neck pain, sciatica, headaches and other painful conditions.

The physicians at IPI have expertise in diagnosing and relieving these problems and many other painful conditions by addressing and fixing the source of the pain in a compassionate manner. Visit http://illinoispain.com for more information or call (847) 289-8822.

ABOUT THE REGENERATIVE STEM CELL INSTITUTE

The Regenerative Stem Cell Institute is devoted to advancing successful outcomes and quality care in the area of adult stem cell regenerative medicine. Treatment is offered for a variety of inflammatory and degenerative conditions under an IRB Approved Research Protocol with Board Certified physicians at eight locations in Chicagoland.

The Regenerative Stem Cell Institute is now accepting new patients who may benefit from regenerative medicine. For more information visit: http://www.StemCellDr.com

David Greene, US Lead Network, http://usleadnetwork.net, +1 (602) 677-8981, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.